Mutations in DNA damage responsepathways as a potentialbiomarker for immune checkpoint blockade efficacy: evidencefrom a seven-cancer immunotherapy cohort


原创 科技辣妈 桓峰基因 2022-05-22 20:41


https://mp.weixin.qq.com/s?__biz=MzU0NDY2NTUwOA==&mid=2247487166&idx=1&sn=34ecb878a14e4be7cd5f1d75edd06efc
--
FROM 59.41.66.*

References：

1. Zhang W, Zhang L, Jiang H, Li Y, Wang S, Wang Q. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort. Aging (Albany NY). 2021;13(21):24136-24154. doi:10.18632/aging.203670

2. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. 2018. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Resarch.

3. Revathidevi S, Murugan AK, Nakaoka H, Inoue I, Munirajan AK. APOBEC: A molecular driver in cervical cancer pathogenesis. Cancer Lett. 2021;496:104-116. doi:10.1016/j.canlet.2020.10.004

4. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer [published correction appears in Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin]]. Nature. 2013;500(7463):415-421. doi:10.1038/nature12477
--
FROM 59.41.66.*